{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:16:02Z","timestamp":1789902962007,"version":"4.0.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pharmaceutical Division"},{"DOI":"10.13039\/100013711","name":"Bayer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The North American Pivotal Trial was designed to investigate the efficacy and safety of vardenafil in males with erectile dysfunction (ED).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>In this randomized, double-blind, placebo-controlled, multicenter, fixed-dose, parallel group, 6-month study, vardenafil at three doses (5\u2003mg, 10\u2003mg, and 20\u2003mg) was compared to placebo with the primary efficacy variables being the International Index of Erectile Function (IIEF) Erectile Function (EF) domain score and per patient diary response success rates for penetration and maintenance of erection through completion of intercourse. Additional efficacy variables included IIEF domain scores measuring intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction. Diary entries for overall per patient satisfaction rates for hardness and sexual experience were also measured. Improvements in quality of sexual life were assessed using the Fugl-Meyer quality of life (QoL) questionnaire.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Compared to placebo, patients taking 10\u2003mg and 20\u2003mg doses of vardenafil showed statistically significantly greater improvement in IIEF domain scores measuring intercourse satisfaction (10.3 and 10.3 vs. 7.7), orgasmic function (7.1 and 6.9 vs. 5.3), overall satisfaction. (7.1 and 7.1 vs. 5.2) for vardenafil 10\u2003mg and 20\u2003mg vs. placebo, respectively, at last observation carried forward (LOCF). Vardenafil 5\u2003mg was statistically significantly better than placebo for the secondary IIEF domain variables of intercourse satisfaction (8.9 vs. 7.7) and overall satisfaction (6.3 vs. 5.2) for vardenafil vs. placebo, respectively, at LOCF. Per patient satisfaction rates for the secondary diary variables measuring erection hardness (38%, 52%, 58% and 18%) and overall satisfaction (45%, 58%, 62% and 23%) were dose dependent and statistically significantly superior for vardenafil at 5\u2003mg, 10\u2003mg and 20\u2003mg compared with placebo, respectively. Patients\u2019 answers to the Fugl-Meyer QoL questionnaire assessing improvement in sexual life also indicated statistically significant superiority for all doses of vardenafil vs. placebo treatment. The most frequent adverse events (AE) in the 5\u2003mg, 10\u2003mg, and 20\u2003mg of vardenafil and placebo groups, respectively, were: headache (10%, 22%, 21% and 4%), flushing (5%, 10%, 13% and 0%), dyspepsia (1%, 4%, 6% and &amp;lt;\u200a1%), and rhinitis (9%, 14%, 17% and 5%). Most AEs were mild or moderate in severity and transient in nature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Vardenafil was superior to placebo for IIEF domain scores, per patient success rates for diary questions, and assessment of quality of sexual life, in a broad range of patients with ED irrespective of etiology or severity. Vardenafil was generally well tolerated, with most AEs being mild or moderate in severity and transient in nature.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2004.04027.x","type":"journal-article","created":{"date-parts":[[2004,9,13]],"date-time":"2004-09-13T09:44:00Z","timestamp":1095068640000},"page":"185-192","source":"Crossref","is-referenced-by-count":37,"title":["Vardenafil Improves Patient Satisfaction with Erection Hardness, Orgasmic Function, and Overall Sexual Experience, While Improving Quality of Life in Men with Erectile Dysfunction"],"prefix":"10.1093","volume":"1","author":[{"given":"Craig","family":"Donatucci","sequence":"first","affiliation":[{"name":"Duke University Medical Center , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Taylor","sequence":"additional","affiliation":[{"name":"Bayer Healthcare, Pharmaceutical Division , West Haven, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Thibonnier","sequence":"additional","affiliation":[{"name":"Bayer Healthcare, Pharmaceutical Division , West Haven, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Bangerter","sequence":"additional","affiliation":[{"name":"Bayer Healthcare, Pharmaceutical Division , West Haven, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gittelman","sequence":"additional","affiliation":[{"name":"South Florida Medical Research , Aventura, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Casey","sequence":"additional","affiliation":[{"name":"The Male Health Centers , Oakville, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2004,9,1]]},"reference":[{"key":"2024032600063012800_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH consensus development panel on impotence","volume":"270","author":"NIH Consensus Conference.","year":"1993","journal-title":"JAMA"},{"key":"2024032600063012800_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1464-410x.1999.00142.x","article-title":"The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences","volume":"84","author":"Ayta","year":"1999","journal-title":"BJU Int"},{"key":"2024032600063012800_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States: Prevalence and predictors","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"issue":"9A Suppl","key":"2024032600063012800_bib4","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(00)00655-0","article-title":"Diagnosis and treatment of erectile dysfunction","volume":"109","author":"Levine","year":"2000","journal-title":"Am J Med"},{"key":"2024032600063012800_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2024032600063012800_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.ijir.3900457","article-title":"Erectile dysfunction in general medicine practice: Prevalence and clinical correlates","volume":"12","author":"Chew","year":"2000","journal-title":"Int J Impot Res"},{"issue":"5 Suppl","key":"2024032600063012800_bib7","first-page":"5","article-title":"Exploring the relationship between depression and erectile dysfunction in aging men","volume":"63","author":"Seidman","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"2024032600063012800_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11934-001-0040-x","article-title":"Sexual dysfunction and depression: Etiology, prevalence, and treatment","volume":"2","author":"Shabsigh","year":"2001","journal-title":"Curr Urol Rep"},{"key":"2024032600063012800_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/014850102753385161","article-title":"Evaluation of health-related quality of life in patients treated for erectile dysfunction with Viagra (sildenafil citrate) using SF-36 score","volume":"48","author":"Fujisawa","year":"2002","journal-title":"Arch Androl"},{"key":"2024032600063012800_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/1531-8249(199907)46:1<15::AID-ANA5>3.0.CO;2-U","article-title":"Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury","volume":"46","author":"Giuliano","year":"1999","journal-title":"Ann Neurol"},{"key":"2024032600063012800_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00003495-199957060-00015","article-title":"Sildenafil: A review of its use in erectile dysfunction","volume":"57","author":"Langtry","year":"1999","journal-title":"Drugs"},{"key":"2024032600063012800_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0022-5347(05)67225-4","article-title":"Erectile dysfunction in patients with spina bifida is a treatable condition","volume":"164","author":"Palmer","year":"2000","journal-title":"J Urol"},{"key":"2024032600063012800_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1365-2605.2002.00320.x","article-title":"The clinical studies of sildenafil for the ageing male","volume":"25","author":"Tsujimura","year":"2002","journal-title":"Int J Androl"},{"key":"2024032600063012800_bib14","doi-asserted-by":"crossref","first-page":"M113","DOI":"10.1093\/gerona\/56.2.M113","article-title":"Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: A subgroup analysis","volume":"56","author":"Wagner","year":"2001","journal-title":"J Gerontol a Biol Sci Med Sci"},{"key":"2024032600063012800_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1742-1241.2002.tb11260.x","article-title":"Tadalafil (cialis (trademark)) for men with erectile dysfunction","volume":"56","author":"Eardley","year":"2002","journal-title":"Int J Clin Pract"},{"key":"2024032600063012800_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/sj.ijir.3900713","article-title":"The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial","volume":"13","author":"Porst","year":"2001","journal-title":"Int J Impot Res"},{"key":"2024032600063012800_bib17","volume-title":"Vardenafil improves erectile dysfunction in men with erectile dysfunction regardless of etiology or baseline severity","author":"Mirone","year":"2003"},{"key":"2024032600063012800_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0090-4295(03)00491-6","article-title":"Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups","volume":"62","author":"Porst","year":"2003","journal-title":"Urology"},{"key":"2024032600063012800_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1939-4640.2002.tb02332.x","article-title":"Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Hellstrom","year":"2002","journal-title":"J Androl"},{"key":"2024032600063012800_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0090-4295(03)00115-8","article-title":"Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial","volume":"61","author":"Hellstrom","year":"2003","journal-title":"Urology"},{"key":"2024032600063012800_bib21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0022-5347(05)65673-X","article-title":"Improvement in emotional well-being and relationships of users of sildenafil","volume":"166","author":"Paige","year":"2001","journal-title":"J Urol"},{"key":"2024032600063012800_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-2001-14277","article-title":"Quality of partnership in patients with erectile dysfunction after sildenafil treatment","volume":"34","author":"Muller","year":"2001","journal-title":"Pharmacopsychiatry"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515300795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515300795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/1\/2\/185\/47522071\/jsm_1_2_185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/1\/2\/185\/47522071\/jsm_1_2_185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:03:22Z","timestamp":1711415002000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/1\/2\/185\/6863001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,9,1]]},"published-print":{"date-parts":[[2004,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2004.04027.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004,9]]},"published":{"date-parts":[[2004,9,1]]}}}